Journal
ANTIVIRAL RESEARCH
Volume 127, Issue -, Pages 79-89Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2016.01.007
Keywords
L polymerase; Phosphorylation; Protein phosphatase 1; Antiviral agent; Rift valley fever virus; Bunyaviridae
Categories
Funding
- NIH [1R15AI100001-01A1, AI101772, AI117445, P50HL118006, 5G12MD007597, U19 AI109664-01]
- District of Columbia Center for AIDS Research grant [1P30AI117970]
Ask authors/readers for more resources
Rift Valley fever virus (RVFV), genus Phlebovirus family Bunyaviridae, is an arthropod-borne virus endemic throughout sub-Saharan Africa. Recent outbreaks have resulted in cyclic epidemics with an increasing geographic footprint, devastating both livestock and human populations. Despite being recognized as an emerging threat, relatively little is known about the virulence mechanisnis and host interactions of RVFV. To date there are no FDA approved therapeutics or vaccines for RVF and there is an urgent need for their development. The Ser/Thr protein phosphatase 1 (PP1) has previously been shown to play a significant role in the replication of several viruses. Here we demonstrate for the first time that PP1 plays a prominent role in RVFV replication early on during the viral life cycle. Both siRNA knockdown of PP1 alpha and a novel PP1-targeting small molecule compound 1E7-03, resulted in decreased viral titers across several cell lines. Deregulation of PP1 was found to inhibit viral RNA production, potentially through the disruption of viral RNA transcript/protein interactions, and indicates a potential link between PP1 alpha and the viral L polymerase and nucleoprotein. These results indicate that PP1 activity is important for RVFV replication early on during the viral life cycle and may prove an attractive therapeutic target. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available